Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Famitinib |
Synonyms | |
Therapy Description |
Famitinib (SHR1020) is an analog of Sutent (sunitinib), a receptor tyrosine kinase (RTK) inhibitor, which inhibits receptor tyrosine kinases including c-Kit, VEGFR2/3, PDGFR-beta, RET, and FLT3 to reduce cell proliferation and tumor growth (PMID: 23126373, PMID: 30382933). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Famitinib | SHR1020|SHR-1020 | FLT3 Inhibitor 69 KIT Inhibitor 57 PDGFR-beta Inhibitor 14 RET Inhibitor 53 VEGFR2 Inhibitor 37 VEGFR3 Inhibitor 6 | Famitinib (SHR1020) is an analog of Sutent (sunitinib), a receptor tyrosine kinase (RTK) inhibitor, which inhibits receptor tyrosine kinases including c-Kit, VEGFR2/3, PDGFR-beta, RET, and FLT3 to reduce cell proliferation and tumor growth (PMID: 23126373, PMID: 30382933). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|